MRI-Guided Region-of-Interest Delineation Is Comparable to Manual Delineation in Dopamine Transporter SPECT Quantification in Patients: A Reproducibility Study
暂无分享,去创建一个
Claus Svarer | Robin de Nijs | Gerda Thomsen | Gitte M Knudsen | Morten Ziebell | C. Svarer | G. Knudsen | L. Pinborg | Lars H Pinborg | Aase Wagner | G. Thomsen | A. Wagner | R. de Nijs | Morten Ziebell | Aase Wagner
[1] Denis Guilloteau,et al. PE2I: A Radiopharmaceutical for In vivo Exploration of the Dopamine Transporter , 2008, CNS neuroscience & therapeutics.
[2] M Laruelle,et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[3] S Y Bao,et al. Imaging of Dopamine Transporters With Technetium‐99m TRODAT‐1 and Single Photon Emission Computed Tomography , 2000, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[4] J. Seibyl,et al. Reproducibility of iodine-123-beta-CIT SPECT brain measurement of dopamine transporters. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[5] P. Morrish. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease? , 2003, Movement disorders : official journal of the Movement Disorder Society.
[6] H. Kretschmann,et al. Neuroanatomy and Cranial Computed Tomography , 1986 .
[7] Masanori Ichise,et al. Reproducibility of dopamine transporter density measured with123I-FPCIT SPECT in normal control and Parkinson’s disease patients , 2004, Annals of nuclear medicine.
[8] Willibald Gerschlager,et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT study , 2002, Movement disorders : official journal of the Movement Disorder Society.
[9] Caroline Prunier,et al. Presymptomatic diagnosis of experimental Parkinsonism with 123I-PE2I SPECT , 2003, NeuroImage.
[10] Werner Poewe,et al. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.
[11] W. Weber,et al. Role of DAT‐SPECT in diagnostic work‐up of Parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.
[12] Christine DeLorenzo,et al. Modeling Considerations for In Vivo Quantification of the Dopamine Transporter using [11C]PE2I and Positron Emission Tomography , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[13] C. Svarer,et al. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[14] Olaf B. Paulson,et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps , 2005, NeuroImage.
[15] H. Kung,et al. Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjects. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] J B Habraken,et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson's disease. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[17] J. Seibyl,et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[18] J. Seibyl,et al. Do dopamine agonists or levodopa modify Parkinson's disease progression? , 2002, European journal of neurology.
[19] S. Asenbaum,et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.
[20] C. Svarer,et al. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[21] R. P. Maguire,et al. Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[22] P B Hoffer,et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] L. Regeur,et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Donald Grosset,et al. Role of dopamine transporter imaging in routine clinical practice , 2003, Movement disorders : official journal of the Movement Disorder Society.
[25] W. Hwang,et al. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] Willibald Gerschlager,et al. Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β-CIT SPECT study. , 2002, Movement disorders : official journal of the Movement Disorder Society.
[27] Perry E Radau,et al. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] Søren Holm,et al. Longitudinal assessment of cerebral 5-HT2A receptors in healthy elderly volunteers: an [18F]-altanserin PET study , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[29] Habib Zaidi,et al. Is absolute quantification of dopaminergic neurotransmission studies with 123I SPECT ready for clinical use? , 2008, European Journal of Nuclear Medicine and Molecular Imaging.
[30] R. Haaxma. Neuroanatomy and cranial computed tomography, Hans-Joachim Kretschmann, Wolfgang Weinrich. Georg Thieme Verlag, Stuttgart (1986), 168, figs and tables, DM 198.-., ISBN: 3 13 672601 4 , 1986 .
[31] John S. Fleming,et al. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio , 2006, European Journal of Nuclear Medicine and Molecular Imaging.
[32] W Martin,et al. Downscatter correction and choice of collimator in 123I imaging. , 2006, Physics in medicine and biology.